Cantor Fitzgerald Downgrades Oncothyreon (ONTY) to Hold

Cantor Fitzgerald downgraded Oncothyreon (NASDAQ: ONTY) from Buy to Hold with shares close to their $4 price target.

Analyst Mara Goldstein said, "Our view on the shares has been driven by our belief that the company's early- to mid-stage pipeline plus cash could drive the shares to $4. While the data readout for the ONT-380 breast cancer studies could be an inflection point for the shares, the timing is likely late 2014, suggesting to us that without nearer-term catalysts, greater valuation expansion is not likely to occur."

For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $3.89 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi Downgrades UBS AG (UBSG:SW) (UBS) to Neutral
• Morgan Stanley Downgrades ICICI Prudential Life Insurance Co Ltd. (IPRU:IN) to Equalweight
• Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'